For international orders (non-US), use this site. For US orders only, visit

Archer® FusionPlex® ALK RET ROS1 v2 Kit

The Archer FusionPlex ALK RET ROS1 v2 Kit is a target-enrichment assay that can be used to create libraries for next generation sequencing.Read More...
Select Product(s)

Archer FusionPlex ALK RET ROS1 v2 Kit - 8 reactions


Accessory Products

Archer MBC Adapters A17-A24



Archer MBC Adapters A25-A32



Archer MBC Adapters A33-A40



Archer MBC Adapters A41-A48



Archer SureShot ALK, RET, ROS1 Fusion Controls



Archer SureShot Negative Fusion Controls



Product Highlights

The Archer FusionPlex ALK, RET and ROS1 v2 Kit rapidly detects translocations from total nucleic acid isolated from tumor samples—including FFPE-preserved specimens. Archer’s proprietary Anchored Multiplex PCR (AMPTM) chemistry allows rapid preparation of highly multiplexed next generation sequencing (NGS) libraries for targeted capture of mRNAs produced from fusion genes. The Archer technology permits the simultaneous detection of both known recurrent fusions as well as previously unidentified fusions at key breakpoints in target genes. Archer’s ALK RET ROS1 Kit offers a complete fusion detection solution, from library preparation through data analysis.

  • No prior knowledge of fusion partners and breakpoints required
  • Detection of known and novel gene fusions from as little as 20ng input nucleic acid
  • Objective sequence-based data compared to subjective FISH analysis
  • Novel enrichment chemistry yields high on-target percentage
  • Random start sites improve sequence data quality

See All Illumina Cancer Research Panels


Product Literature

Report on FFPE Extraction Methods

White Paper | PDF 2 MB

PreSeq RNA QC Assay

White Paper | PDF < 1 MB

Archer FusionPlex Assay Targets

Brochure | PDF 1 MB

Archer FusionPlex ALK, RET, ROS1 v2

Brochure | PDF < 1 MB

Manuals and Support Information

All Archer FusionPlex Support 

Related Products

  1. J. M. Heuckmann et al., ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research 17, 7394–7401 (2011).
  2. World Health Organization, Cancer - Fact sheet N°297 (2014).
  3. J. Ferlay et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917 (2010).
  4. D. S. Ettinger et al., Non-small cell lung cancer. J Natl Compr Canc Netw 8, 740–801 (2010).
  5. A. J. Alberg, M. V. Brock, J. G. Ford, J. M. Samet, S. D. Spivack, Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143, e1S–29S (2013).
  6. J. R. Molina, P. Yang, S. D. Cassivi, S. E. Schild, A. A. Adjei, Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584–594 (2008).
  7. R. E. Shackelford, M. Vora, K. Mayhall, J. Cotelingam, ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer 5, 1–14 (2014).